In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singulex, Inc.

https://www.singulex.com/

Latest From Singulex, Inc.

Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug

Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.

Financing Innovation

Inivata Names Clive Morris New CEO

Inivata's Chief Medical Officer Clive Morris will take over as CEO of the liquid biopsy company. Former CEO Michael Stocum departed earlier this year.

Executive Changes Companies

Singulex And Qiagen Partner In Personalized Medicine

Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.

Deals In Vitro Diagnostics

Singulex’ Cardiac Troponin Test Predicts Cardiac Risk In Stable Patients

Results of from a new analysis of plasma samples from an old statin trial suggest that Singulex’ high-sensitivity cardiac troponin test can track the cardiovascular risk in stable patients with ischemic heart disease.

Cardiology In Vitro Diagnostics
See All

Company Information

  • Industry
  • Digital Health
  • Services
  • Services
    • Diagnostic Imaging Services
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
UsernamePublicRestriction

Register